Iambic Therapeutics Presents Updated Clinical Results From Its IAM1363 Inhibitor At ESMO Congress 2026

Benzinga · 1d ago

Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced updated clinical data for IAM1363, a selective and brain-penetrant HER2 tyrosine kinase inhibitor (TKI), from its ongoing Phase 1/1b clinical trial. The data, which showed durable anti-tumor activity, intracranial responses and a favorable tolerability profile in heavily pretreated participants with HER2-altered advanced cancers, were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid on October 23, 2026.